{"id":14205,"date":"2020-11-02T21:58:00","date_gmt":"2020-11-02T21:58:00","guid":{"rendered":"http:\/\/patrocinados.estadao.com.br\/medialab\/agenciacomunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/"},"modified":"2020-11-02T21:58:00","modified_gmt":"2020-11-02T21:58:00","slug":"pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/","title":{"rendered":"PR NEWSWIRE &#8211; BRASIL :: RevImmune avan\u00e7a com nova imunoterapia para COVID-19"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h1 class=\"xn-hedline\">RevImmune avan\u00e7a com nova imunoterapia para COVID-19<\/h1>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<p class=\"xn-dateline\">BETHESDA, Maryland,, 2 de novembro de 2020<\/p>\n<\/div>\n<div class=\"xn-content\">\n<span class=\"xn-location\">BETHESDA, Maryland<\/span>,, 2 de novembro de 2020 \/PRNewswire\/ &#8212; A RevImmune, uma empresa privada de biotecnologia com sede em <span class=\"xn-location\">Paris<\/span>, Fran\u00e7a e <span class=\"xn-location\">Bethesda<\/span>, EUA, e que trabalha no desenvolvimento da CYT107 (Interleucina-7 humana recombinante) para doen\u00e7as infecciosas, sepse e c\u00e2ncer, anunciou hoje que seu ensaio cl\u00ednico internacional, randomizado e controlado &#8220;ILIAD-7&#8221; Fase II em pacientes em estado de sa\u00fade grave por causa da COVID-19, est\u00e1 aceitando pacientes em 5 locais nos EUA\u00a0. O ensaio j\u00e1 est\u00e1 em andamento h\u00e1 algum tempo no Reino Unido e na Fran\u00e7a e come\u00e7ar\u00e1 em breve no Brasil.\u00a0 <\/p>\n<div id=\"prni_dvprnejpg8264left\"><img decoding=\"async\" alt=\" \" src=\"https:\/\/mma.prnewswire.com\/media\/1196997\/RevImmune_Logo.jpg\" \/><\/div>\n<p>O ensaio cl\u00ednico ILIAD-7 come\u00e7ou a inscrever pacientes no Barnes Jewish Hospital-Missouri Baptist Medical Center e na <span class=\"xn-org\">Washington University<\/span> em <span class=\"xn-location\">St. Louis<\/span> e em mais quatro locais: a Cleveland Clinic, o Stony Brook University Hospital, o <span class=\"xn-org\">University of Florida<\/span> Medical Center e o Rutgers New Brunswick Medical Center. Locai adicionais ser\u00e3o acrescentados em breve.<\/p>\n<p>O Dr. <span class=\"xn-person\">Kenneth Remy<\/span>, m\u00e9dico-cientista da <span class=\"xn-org\">Washington University<\/span> em <span class=\"xn-location\">St. Louis<\/span> explica, &#8220;os dados dos \u00faltimos meses de nosso laborat\u00f3rio e uma crescente literatura de outros pesquisadores sobre a COVID-19 demonstraram que os pacientes t\u00eam uma perda prolongada e grave de linf\u00f3citos com uma supress\u00e3o imunol\u00f3gica profunda, em vez de exclusivamente uma tempestade de citocinas.\u00a0Os pacientes que sucumbem \u00e0 COVID-19 t\u00eam uma perda mais grave de linf\u00f3citos e uma alta incid\u00eancia do desenvolvimento de infec\u00e7\u00f5es secund\u00e1rias adquiridas em hospital.&#8221;\u00a0 <\/p>\n<p>A Dra. <span class=\"xn-person\">Vidula Vachharajani<\/span>, Professora de Medicina na Cleveland Clinic Lerner College of Medicine, afirmou que &#8220;a IL-7 oferece uma poss\u00edvel maneira de restaurar a imunidade em pacientes com COVID-19 e pode reduzir a incid\u00eancia de infec\u00e7\u00f5es secund\u00e1rias adquiridas em hospitais.&#8221;\u00a0 <\/p>\n<p>At\u00e9 o momento, a CYT107 foi administrada em ensaios cl\u00ednicos em mais de 500 pacientes com diversas doen\u00e7as infecciosas, sepse e c\u00e2ncer, com excelente perfil de seguran\u00e7a e resultados encorajadores. O principal mecanismo de a\u00e7\u00e3o da CYT107 funciona para restaurar a fun\u00e7\u00e3o dos linf\u00f3citos e aumentar a sua prolifera\u00e7\u00e3o, auxiliando assim na elimina\u00e7\u00e3o dos pat\u00f3genos invasores. <\/p>\n<p>O sucesso inicial com a CYT107 em pacientes criticamente afetados pela COVID-19, publicado no Journal of American Medical Association (JAMA) Open Network em agosto, mostrou que a CYT107 melhorou a contagem absoluta de linf\u00f3citos em 12 pacientes de uso compassivo com COVID-19.\u00a0\u00a0 <\/p>\n<p>O tratamento com CYT107 que est\u00e1 sendo testado no atual ensaio cl\u00ednico randomizado de fase II foi projetado para melhorar a sobrevida em pacientes em estado de sa\u00fade grave com hipoxemia e linfopenia grave (baixas contagens de linf\u00f3citos).\u00a0O estudo est\u00e1 atualmente aceitando pacientes em 5 locais nos EUA e deve continuar at\u00e9 dezembro.<\/p>\n<p>Logotipo &#8211; <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=pt&amp;o=2967871-1&amp;h=2965839749&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2967871-1%26h%3D3579121527%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1196997%252FRevImmune_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1196997%252FRevImmune_Logo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1196997%2FRevImmune_Logo.jpg\" rel=\"noopener\">https:\/\/mma.prnewswire.com\/media\/1196997\/RevImmune_Logo.jpg<\/a><\/p>\n<p>FONTE  RevImmune Inc<\/p>\n<\/div>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT77317&amp;Transmission_Id=202011021947PR_NEWS_LATAM____PT77317&amp;DateId=20201102\" \/><\/p>\n<p>PR NEWSWIRE<\/p>\n","protected":false},"excerpt":{"rendered":"RevImmune avan\u00e7a com nova imunoterapia para COVID-19 PR Newswire BETHESDA, Maryland,, 2 de novembro de 2020 BETHESDA, Maryland,, 2 de novembro de 2020 \/PRNewswire\/ &#8212; A RevImmune, uma empresa","protected":false},"author":1,"featured_media":14206,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[28],"tags":[],"class_list":["post-14205","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-prnewsbrasil"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PR NEWSWIRE - BRASIL :: RevImmune avan\u00e7a com nova imunoterapia para COVID-19 - Ag\u00eancia de Comunica\u00e7\u00e3o<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PR NEWSWIRE - BRASIL :: RevImmune avan\u00e7a com nova imunoterapia para COVID-19 - Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"og:description\" content=\"RevImmune avan\u00e7a com nova imunoterapia para COVID-19 PR Newswire BETHESDA, Maryland,, 2 de novembro de 2020 BETHESDA, Maryland,, 2 de novembro de 2020 \/PRNewswire\/ &#8212; A RevImmune, uma empresa\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-02T21:58:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem-130.png\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"patric_oliveira\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"patric_oliveira\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/\"},\"author\":{\"name\":\"patric_oliveira\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"headline\":\"PR NEWSWIRE &#8211; BRASIL :: RevImmune avan\u00e7a com nova imunoterapia para COVID-19\",\"datePublished\":\"2020-11-02T21:58:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/\"},\"wordCount\":494,\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/medialabimagem-130.png\",\"articleSection\":[\"PR Newswire Brasil\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/\",\"name\":\"PR NEWSWIRE - BRASIL :: RevImmune avan\u00e7a com nova imunoterapia para COVID-19 - Ag\u00eancia de Comunica\u00e7\u00e3o\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/medialabimagem-130.png\",\"datePublished\":\"2020-11-02T21:58:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/#primaryimage\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/medialabimagem-130.png\",\"contentUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/medialabimagem-130.png\",\"width\":600,\"height\":400},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PR NEWSWIRE &#8211; BRASIL :: RevImmune avan\u00e7a com nova imunoterapia para COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\",\"name\":\"Ag\u00eancia de Comunica\u00e7\u00e3o\",\"description\":\"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\",\"name\":\"patric_oliveira\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"caption\":\"patric_oliveira\"},\"sameAs\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"],\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/author\\\/patric_oliveira\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PR NEWSWIRE - BRASIL :: RevImmune avan\u00e7a com nova imunoterapia para COVID-19 - Ag\u00eancia de Comunica\u00e7\u00e3o","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/","og_locale":"pt_BR","og_type":"article","og_title":"PR NEWSWIRE - BRASIL :: RevImmune avan\u00e7a com nova imunoterapia para COVID-19 - Ag\u00eancia de Comunica\u00e7\u00e3o","og_description":"RevImmune avan\u00e7a com nova imunoterapia para COVID-19 PR Newswire BETHESDA, Maryland,, 2 de novembro de 2020 BETHESDA, Maryland,, 2 de novembro de 2020 \/PRNewswire\/ &#8212; A RevImmune, uma empresa","og_url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/","og_site_name":"Ag\u00eancia de Comunica\u00e7\u00e3o","article_published_time":"2020-11-02T21:58:00+00:00","og_image":[{"width":600,"height":400,"url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem-130.png","type":"image\/png"}],"author":"patric_oliveira","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"patric_oliveira","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/#article","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/"},"author":{"name":"patric_oliveira","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"headline":"PR NEWSWIRE &#8211; BRASIL :: RevImmune avan\u00e7a com nova imunoterapia para COVID-19","datePublished":"2020-11-02T21:58:00+00:00","mainEntityOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/"},"wordCount":494,"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem-130.png","articleSection":["PR Newswire Brasil"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/","name":"PR NEWSWIRE - BRASIL :: RevImmune avan\u00e7a com nova imunoterapia para COVID-19 - Ag\u00eancia de Comunica\u00e7\u00e3o","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem-130.png","datePublished":"2020-11-02T21:58:00+00:00","author":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"breadcrumb":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/#primaryimage","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem-130.png","contentUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem-130.png","width":600,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/pr-newswire-brasil-revimmune-avanca-com-nova-imunoterapia-para-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"},{"@type":"ListItem","position":2,"name":"PR NEWSWIRE &#8211; BRASIL :: RevImmune avan\u00e7a com nova imunoterapia para COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/","name":"Ag\u00eancia de Comunica\u00e7\u00e3o","description":"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37","name":"patric_oliveira","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","caption":"patric_oliveira"},"sameAs":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"],"url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/author\/patric_oliveira\/"}]}},"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/14205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=14205"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/14205\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media\/14206"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=14205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=14205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=14205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}